<div>
  <ul>
    <li>
      <p>
        California-based AI biotechnology company Verge Genomics and Ferrer have entered a collaboration to co-develop an AI-discovered drug, VRG50635, for the treatment of amyotrophic lateral sclerosis (ALS).
      </p>
    </li>
    <li>
      <p>
        Under the terms of the agreement, Verge Genomics will utilize its AI-powered platform to identify therapeutic targets while Ferrer will get exclusive rights to develop and sell the drug for ALS in several regions excluding the US. Ferrer will combine its extensive global experience in clinical development, manufacturing, and commercialization.
      </p>
    </li>
    <li>
      <p>
        As of March 2024, the drug is being studied in Phase 1b clinical trials&nbsp;across Canada and Europe.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240325739095/en/Verge-Genomics-and-Ferrer-Announce-Agreement-to-Co-Develop-Clinical-Stage-ALS-Therapy-VRG50635">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

PROMINENT_CATEGORY

<div>
 <p>Verge Genomics, a California-based AI biotechnology company, has entered into a partnership with Ferrer to develop an AI-discovered drug, VRG50635, intended for the treatment of Amyotrophic Lateral Sclerosis (ALS). </p>
 <p>According to the agreement's terms, Verge Genomics will use its AI technology to identify possible therapeutic targets. In contrast, Ferrer acquires exclusive rights for the development and sale of the drug for ALS in several regions, excluding the United States. Ferrer will use its vast global experience in clinical development, manufacture, and commercialization in this collaboration.</p>
 <p>The drug, VRG50635, is currently being studied in Phase 1b clinical trials across Canada and Europe, as of March 2024.</p>
 
</div>

Verge Genomics and Ferrer partner to develop AI-based treatment for amyotrophic lateral sclerosis

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>California-based AI biotechnology company Verge Genomics has partnered with the Pritzker Neuropsychiatric Disorders Research Consortium to study schizophrenia using AI and postmortem brain tissue.</p></li>
  <li><p>The collaboration will utilize Verge Genomics' AI-powered CONVERGE platform to analyze data from schizophrenic and healthy brain tissue. The goal is to discover new therapeutic targets for this complex disorder.</p></li>
 </ul>
 
</div>

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium partner to discover treatment for schizophrenia

<div>
 <ul>
  <li><p>California-based AI biotechnology company Verge Genomics has teamed up with the Pritzker Neuropsychiatric Disorders Research Consortium to study schizophrenia's molecular processes using AI and postmortem brain tissue.</p></li>
  <li><p>The collaboration will utilize Verge Genomics' AI-powered CONVERGE platform to analyze data from schizophrenia patient brain tissue and healthy donor tissue. Through combining resources and expertise, the partnership aims to discover new therapeutic targets for treating schizophrenia, a complex neurological disorder.</p></li>
 </ul>
 
</div>

California-based biotech company Verge Genomics has announced a multi-target partnership with Alexion, a subsidiary of AstraZeneca, to identify new drug targets for rare neurodegenerative and neuromuscular diseases. The four-year agreement will see Verge Genomics receive up to $42 million in upfront fees, equity, and near-term payments, with a potential deal value of $840 million plus royalties. The collaboration will use Verge's CONVERGE platform, which combines human tissue datasets with AI, to identify and validate therapeutic targets for rare diseases. Alexion will have the option to license and advance successful targets through clinical development and commercialization. AstraZeneca will also take an equity position in Verge Genomics.

Verge Genomics collaborates with AstraZeneca subsidiary to discover drugs for rare neurodegenerative and neuromuscular diseases

California-based AI biotechnology company Verge Genomics has announced a multi-target partnership with Alexion, a subsidiary of AstraZeneca, aimed at identifying new drug targets for rare neurodegenerative and neuromuscular diseases. This four-year agreement will provide Verge with up to $42 million, consisting of an upfront fee, equity, and near-term payments. The collaboration will utilize Verge's CONVERGE platform, which combines AI with human tissue datasets, to identify and validate therapeutic targets for rare diseases. Alexion will have the option to license and advance successful targets through clinical development and commercialization. AstraZeneca will also take an equity position in Verge Genomics as part of the partnership.

All Updates

Verge Genomics and Ferrer partner to develop AI-based treatment for amyotrophic lateral sclerosis

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium partner to discover treatment for schizophrenia

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium partner to discover treatment for schizophrenia

Verge Genomics collaborates with AstraZeneca subsidiary to discover drugs for rare neurodegenerative and neuromuscular diseases

Verge Genomics collaborates with AstraZeneca subsidiary to discover drugs for rare neurodegenerative and neuromuscular diseases

Verge Genomics doses the first patient with its AI-discovered drug

Verge Genomics raises USD 98 million in oversubscribed Series B funding

Verge Genomics raises USD 98 million in oversubscribed Series B funding

Verge Genomics enters collaboration with Eli Lilly securing USD 25 million upfront